Brief: Candel Therapeutics Q4 Net Income USD -29.496 Million
12/03/2026 12:05
Mar 12 (Reuters) - Candel Therapeutics Q4 operating expenses USD 15.752 million. Q4 income from operations USD -15.752 million vs. IBES estimate USD -13.9 million Q4 basic EPS USD -0.54
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Candel Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Candel Therapeutics Reports Second Quarter 2026 Financial Results And Recent Corporate Highlights
Candel Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)